Appendix B
Workshop Agenda
TUESDAY, JUNE 12, 2018
8:30 am ET | Welcome Remarks |
Peter Daszak, Chair, Forum on Microbial Threats | |
The Neglected Dimension of Economic Security: Managing Microbial Threats (by video) | |
Lawrence H. Summers, Harvard University | |
Workshop Overview and Goals | |
Peter Sands, The Global Fund to Fight AIDS, Tuberculosis and Malaria |
Session I: The Economic Cost of Microbial Threats
Part A: The Economic Risk of Endemic Infectious Diseases
Thomas Inglesby, Moderator
9:10 am | The Economic Case for Eradicating Polio |
Kimberly Thompson, Kid Risk, Inc. | |
Epidemic to Endemic—The Economic Impact of HIV/AIDS | |
Katharina Hauck, Imperial College London |
Costing of Tuberculosis Control | |
Anna Vassall, London School of Hygiene & Tropical Medicine; University of Amsterdam | |
9:45 am | Discussion |
10:20 am | Break |
Part B: Economics and Modeling of Emerging Infectious Diseases and Biological Risks
Rebecca Katz, Moderator
10:35 am | The Cost of Pandemic Influenza—What Has Changed and What Have We Learned 100 Years Later? |
Martin Isaac Meltzer, U.S. Centers for Disease Control and Prevention | |
Assessing Economic Vulnerability to Emerging Infectious Disease Outbreaks—Ebola Versus Zika | |
Anas El Turabi, Harvard University | |
Epidemic Risk Modeling—How Can We Measure the Impact of Aversion Behavior and Cascading Social Responses? | |
Carlos Castillo-Chavez, Arizona State University | |
The Global Catastrophic Biological Risks | |
Thomas Inglesby, Johns Hopkins Bloomberg School of Public Health | |
11:30 am | Discussion |
12:00 pm | Lunch |
Part C: The Cost of Antimicrobial Resistance (AMR)
Keiji Fukuda, Moderator
1:00 pm | Considerations for Estimating the Cost of AMR—Direct Versus Indirect Costs |
Mukesh Chawla, World Bank |
Cost-Effectiveness of Interventions to Limit the Spread of AMR—A Perspective from the Organisation for Economic Co-operation and Development (OECD) | |
Mark Pearson, OECD | |
The Impact of AMR Beyond the Health Sector—How to Make the Investment Case for Controlling AMR? | |
Ramanan Laxminarayan, Center for Disease Dynamics, Economics & Policy | |
1:40 pm | Discussion |
Session II: The Economic Cost of Preparedness for Microbial Threats
Part A: National Preparedness
Beth Cameron, Moderator
2:10 pm | Economics of National Preparedness to Fight Against Microbial Threats |
Tolbert Nyenswah, National Public Health Institute of Liberia | |
Cost-Benefit Analysis of Outbreak Response in the Context of the Monitoring and Evaluation of the International Health Regulations | |
Andreas Gilsdorf, Consultant for Public Health Security | |
Economic Impacts of Financing Performance of Veterinary Services Gap Analysis | |
Franck Berthe, World Bank | |
The Cost of Implementing a One Health Approach to Combat Microbial Threats | |
Katherine Lee, University of Idaho | |
3:00 pm | Discussion |
3:40 pm | Break |
Part B: Accelerating Research and Development of Medical Products
Jami Taylor, Moderator
3:55 pm | Panel Discussion |
Paul Schaper, Merck & Co., Inc. | |
Joanna Wolkowski, Pfizer Inc. | |
Thomas Cueni, International Federation of Pharmaceutical Manufacturers & Associations | |
Jonathan Kfoury, L.E.K. Consulting | |
4:20 pm | Discussion |
5:25 pm | Wrap Up |
Peter Sands, Workshop Chair | |
5:35 pm | Reception |
WEDNESDAY, JUNE 13, 2018
8:30 am ET | Welcome and Recap Day 1 |
Peter Sands, Workshop Chair |
Session III: Investing in Preparedness for Microbial Threats
Part A: Investing in Sustainable Solutions
Peter Sands, Moderator
8:40 am | Development Assistance for Health: Economic Perspectives to Counter Microbial Threats |
Dean Jamison, University of California, San Francisco; University of Washington | |
Overcoming Economic Bottlenecks in Delivering Medical Products to Address Microbial Threats Across Africa | |
Tana Zulu Holt, McKinsey and Co. | |
9:05 am | Discussion |
Part B: Breakout Session
9:25 am | Introduction to Session |
Suerie Moon, The Graduate Institute, Geneva | |
9:30 am | (mobilize to breakout room) |
9:35 am | Breakout Session |
The purpose of the breakout session is to identify priority next steps and develop actionable strategies to achieve those next steps across the three topics below. | |
Group 1: Modeling the Economic Risks of Emerging Infectious Diseases | |
Peter Daszak, EcoHealth Alliance | |
Group 2: Creating a Sustainable Economic Model to Stimulate Research and Development for Antibiotics | |
Ed Whiting, Wellcome Trust | |
Group 3: Incentives for National Governments to Invest in Preparedness: Incorporating Economic Risks of Outbreaks into Macroeconomic Assessments | |
Mukesh Chawla, World Bank | |
10:50 am | Break |
11:30 am | Breakout Group Reports |
Suerie Moon, Moderator | |
Group 1: Modeling the Economic Risks of Emerging Infectious Diseases | |
Peter Daszak, EcoHealth Alliance | |
Group 2: Creating a Sustainable Economic Model to Stimulate Research and Development for Antibiotics | |
Ed Whiting, Wellcome Trust | |
Group 3: Incentives for National Governments to Invest in Preparedness: Incorporating Economic Risks of Outbreaks into Macroeconomic Assessments | |
Anas El Turabi, Harvard University | |
11:30 am | Synthesis and General Discussion |
Suerie Moon, Moderator | |
12:15 pm | Closing Remarks |
Peter Sands, Workshop Chair | |
Peter Daszak, Chair, Forum on Microbial Threats | |
12:30 pm | Adjourn |